Logo
x

Search category

Subscribe Now

Treat

Agenus Reports the Withdrawal of BLA for Balstilimab to Treat Cervical Cancer

Agenus Reports the Withdrawal of BLA for Balstilimab to Treat Cervical Cancer

  • October 25, 2021
Agenus Reports the Withdrawal of BLA for Balstilimab to Treat Cervical Cancer

Agenus Reports the Withdrawal of BLA for Balstilimab to Treat Cervical Cancer

  • October 25, 2021
Gilead's Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Low-Dose Tablet Receives the US FDA's Approval for Expanded Indication to Treat HIV-1

Gilead's Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Low-Dose Tablet Receives the US FDA's Approval for Expanded In...

  • October 19, 2021
Gilead's Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Low-Dose Tablet Receives the US FDA's Approval for Expanded Indication to Treat HIV-1

Gilead's Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Low-Dose Tablet Receives the US FDA's Approval for Expanded In...

  • October 19, 2021
Spark Signs an Exclusive Global Licensing Agreement with CombiGene for CG01 to Treat Focal Epilepsy

Spark Signs an Exclusive Global Licensing Agreement with CombiGene for CG01 to Treat Focal Epilepsy

  • October 13, 2021
Spark Signs an Exclusive Global Licensing Agreement with CombiGene for CG01 to Treat Focal Epilepsy

Spark Signs an Exclusive Global Licensing Agreement with CombiGene for CG01 to Treat Focal Epilepsy

  • October 13, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.